DAWN - NASDAQ
Day One Biopharmaceuticals, Inc.
$21.53
+0.0000%Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotDay One Biopharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Day One Biopharmaceuticals, Inc. Income Statement
DAWN • NASDAQ
| Day One Biopharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
158.2M | 131.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(17.2M) | (5.3M) | (383K) | (531K) | (199K) | (155K) | (0.0) | |
141M | 125.9M | -383K | -531K | -199K | -155K | 0.0 | |
OPERATING INCOME | |||||||
(268.7M) | (343.2M) | (205.7M) | (146.4M) | (72.5M) | (13.6M) | (14.9M) | |
(120.6M) | (115.5M) | (75.2M) | (60.8M) | (29M) | (4.5M) | (1M) | |
(148.1M) | (227.7M) | (130.5M) | (85.6M) | (43.6M) | (9.1M) | (13.9M) | |
-127.8M | -217.3M | -206.1M | -146.9M | -72.7M | -13.8M | -14.9M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (30K) | (2.1M) | |
18.5M | 19.7M | 17.2M | 4.7M | 4K | -30K | -2.1M | |
18.5M | 128.9M | 17.1M | 4.7M | -11K | -30.1M | -2.1M | |
-109.3M | -88.4M | -188.9M | -142.2M | -72.8M | -43.8M | -17M | |
NET INCOME | |||||||
-2M | (7.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-107.3M | -95.5M | -188.9M | -142.2M | -70.6M | -40.5M | -12.6M |
SEC Filings
DAWN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 23, 2026 | April 22, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 17, 2026 | December 31, 2025 | 2025 | |
8-K/A 8-K/A 2026 (Amended) N/A | March 09, 2026 | January 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 24, 2025 | November 24, 2025 | 2025 |
Related Guides
Continue your DAWN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.